A1C reduction comparison A network meta-analysis published in BMC Endocrine Disorders in 2024, analyzing 26 clinical studies, found the following A1C reductions compared to placebo: Tirzepatide 15mg: -2.24% A1C reduction Tirzepatide 10mg: -1.99% A1C reduction Tirzepatide 5mg: -1.82% A1C reduction Liraglutide 1.8mg: approximately -1.3% A1C reduction Liraglutide 1.2mg: -1.23% A1C reduction At the highest respective doses, tirzepatide reduces A1C by nearly twice as much as liraglutide
A study published last month suggested the drugs could result in reduced hip and spine bone mineral density when used without exercise, adding to concerns patients could lose muscle mass while taking GLP-1 drugs for weight loss
This is the primary eligibility threshold established in clinical trials for chronic weight management
Key Differences Semaglutide: GLP-1 only
Based on the responses, Remedy Meds pairs you with a licensed healthcare provider who reviews your information and approves or denies your eligibility for treatment
The microdose approach represents a clinically sound starting strategy that many patients prefer before advancing to standard therapeutic concentrations
